Medchem spotlights spermidine trihydrochloride powder at CPHI

Essence Medchem Co., Ltd. is showcasing spermidine trihydrochloride powder as a pharma intermediate at CPHI, pitching it to drug developers that need a stable, scalable raw material for formulation work. The company says its U.S.-stored inventory, documentation package and batch testing are designed to support global manufacturing and regulatory review.

Why it matters: - Spermidine trihydrochloride is being positioned as a more stable manufacturing input for pharmaceutical formulations that can be sensitive to moisture, heat and handling. - Medchem is targeting drug developers and technical purchasers that need consistent intermediates for scale-up, quality control and regulatory documentation. - The company says U.S.-based inventory can shorten transit times from weeks to days for North American customers.

What happened: - Essence Medchem Co., Ltd. introduced its spermidine trihydrochloride powder at the CPHI exhibition. - The company presented the material as a pharma intermediate rather than a standard dietary supplement ingredient. - Medchem identified the product as a highly stable crystalline salt intermediate for formulation development. - The company also promoted its broader manufacturing portfolio, which includes NMN, NR, NAD+, equol, l-ergothioneine, ectoine, reduced glutathione and several magnesium compounds.

The details: - Spermidine trihydrochloride is described as a stable, free-flowing crystalline powder. - The trihydrochloride salt form reduces the hygroscopic behavior seen in free-base spermidine. - The salt form is designed to resist moisture absorption during handling and high-speed processing. - The material has an elevated melting point intended to support mechanical blending, milling and direct compression. - The salt form is intended to dissolve rapidly and uniformly in aqueous systems. - Medchem says optimized crystallization controls particle shape and reduces moisture traps in the crystal matrix. - The company says that helps the intermediate remain stable during long-term storage and bulk handling. - Each batch is tested by high-performance liquid chromatography to verify a minimum purity of 98%. - The testing is intended to monitor baseline parameters and screen for unreacted precursors and degradation products. - Medchem says it provides technical master files beyond a standard certificate of analysis. - Those files include structural validation data from nuclear magnetic resonance spectroscopy and mass spectrometry. - The documentation also includes synthetic pathway details and long-term stability data across climatic zones. - The company says its facilities hold ISO 9001, ISO 22000 and FSSC 22000 certifications. - Medchem also says its facilities meet Halal and Kosher requirements and are registered with the FDA. - The company says it can tailor particle size distribution through controlled milling. - Medchem says it can also set impurity thresholds to match customer specifications. - The company says it maintains dedicated warehouses in the United States. - Medchem says those warehouses support faster access for North American partners and help buffer against transport disruptions. - The product is being discussed in the context of research into autophagy and cellular maintenance. - The company says the material can be used in direct-compression tablets, two-piece hard capsules, orally disintegrating tablets and sterile powder precursors.

Between the lines: - Medchem is framing the product less as a commodity ingredient and more as a technical platform for pharmaceutical development. - The emphasis on documentation, impurity control and local inventory signals that regulatory readiness and supply-chain reliability are part of the sales pitch. - The company is also using CPHI to reinforce its role as a cross-border supplier for both development-stage and commercial-stage customers.

What's next: - Medchem says buyers can request technical specifications, batch documentation or a customized consultation through its website: the company's announcement - The company is likely to continue promoting the material to global formulators and procurement teams attending CPHI. - North American customers may be the fastest route to near-term sales if the U.S. warehouse strategy holds up in practice.

The bottom line: - Medchem is betting that pharma buyers will pay for a stable, well-documented spermidine intermediate that is ready for formulation and supply-chain scrutiny.